Selected publications

  1. Tulchinsky E. 2017. Colorectal cancer cells use the negative feedback regulators of WNT signalling to activate epithelial-mesenchymal transition pathways. Gut. doi: 10.1136/gutjnl-2016-313185. Invited commentary.
  2. Ramsdale R, Jorissen RN, Li FZ, Al-Obaidi S, Ward T, Sheppard KE, Bukczynska PE, Young RJ, Boyle SE, Shackleton M, Bollag G, Long GV, Tulchinsky E, Rizos H, Pearson RB, McArthur GA, Dhillon AS, Ferrao PT. 2015. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. Sci Signal. 8, ra82.
  3. Gilan O, Diesch J, Amalia M, Jastrzebski K, Chueh AC, Verrills NM, Pearson RB, Mariadason JM, Tulchinsky E, Hannan RD, Dhillon AS. 2015. PR55α-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity. Oncogene. 34, 1340.
  4. Dhillon AS, Tulchinsky E. 2015. FRA-1 as a driver of tumour heterogeneity: a nexus between oncogenes and embryonic signalling pathways in cancer. Oncogene. 34, 4421-4428. Invited Review
  5. Diesch J, Sanij E, Gilan O, Love C, Tran H, Fleming NI, Ellul J, Amalia M, Haviv I, Pearson RB, Tulchinsky E, Mariadason JM, Sieber OM, Hannan RD, Dhillon AS. 2014. Widespread FRA1-dependent control of mesenchymal transdifferentiation programs in colorectal cancer cells. PLoS One, 9, e88950.
  6. Tulchinsky E, Pringle JH, Caramel J, Ansieau S. 2014. Plasticity of melanoma and EMT-TF reprogramming. Oncotarget. 5: 1-2. Invited commentary
  7. Caramel J, Papadogeorgakis E, Hill L, Browne GJ, Richard G, Wierinckx A, Saldanha G, Osborne J, Hutchinson P, Tse G, Lachuer J, Puisieux A, Pringle JH, Ansieau S, Tulchinsky E. 2013. A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell, 24, 466-480.
  8. Pakay JL, Diesch J, Gilan O, Yip Y-Y, Sayan AE, Kolch W, Mariadason JM, Hannan RD, Tulchinsky E, Dhillon AS. 2012. TBP-1 subunit of the 19S proteasome cooperates with an ERK-regulated degron to regulate turnover of the Fra-1/AP-1 transcription factor. Oncogene, 31, 1817-1824.
  9. Sayan A.E., Stanford R., Vickery R., Grigorenko E., Diesch J., Kulbicki K., Edwards R., Pal R., Grieves P., Jariel-Encontre I., Piechaczyk M., Mellon J.K., Kriajevska M., Dhillon A.S., Tulchinsky E. 2012. Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL. Oncogene, 31, 1493-1503.
  10. Sayan A.E., Griffiths R.T.L., Pal R., Browne G.J., Ruddick A., Yagci T., Edwards R., Mayar N.J., Quasi H., Gayal S., Fernandez S., Straatman K., Jones G.D.D., Bowman K., Colquhoun A., Mellon J.K., Kriajevska M., Tulchinsky E. 2009. SIP1 protein protects cells from apoptosis and has independent prognostic value in bladder cancer. Proc Natl Acad Sci USA, 106, 14884-14889.
  11. Mejlvang J., Kriajevska M., Vandewalle C., Chernova T., Berx G., Mellon J.K., and Tulchinsky E. 2007. Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. Mol Biol Cell, 18, 4614-4624.
  12. Mejlvang J, Kriajevska M, Berditchevski F, Lukanidin EM, Mellon JK, and Tulchinsky EM. 2007. Characterization of E-cadherin-dependent and -independent events in a new model of c-Fos-mediated epithelial-mesenchymal transition. Exp Cell Res, 313, 380-393.
  13. Andersen H., Mejlvang J., Mahmood S., Gromova I., Gromov P., Lukanidin E., Kriajevska M., Mellon K. and Tulchinsky E. 2005. Immediate and delayed effects of E-cadherin inhibition on gene regulation and cell motility in human epidermoid carcinoma cells. Mol Cell Biol, 25, 9138-9150.

Share this page:

NEWS

Powerful pre-clinical platform for anti-cancer drug and biomarker discovery

Pre-clinical models that can accurately predict outcomes in the clinic are much sort after in the field of cancer drug discovery and development.  Read about how patient derived explants offer many advantages and are the powerful model of choice. A copy of the review, published in the British Journal of Cancer, is available by clicking this link: PDE Platform

---------------------------------

SEND Study Success

Congratulations to Chris Avery, who with collaborating colleagues published findings of the SEND study, a multi-centre randomised trial using two different surgical protocols for mouth cancer treatment.  A nationwide first for this type of trial, using real-world data.  The paper, published in the British Journal of Cancer, is available by clicking this link: SEND Paper

---------------------------------

Centre Health and Wellbeing Group
Join up for a walk on the park Friday lunchtime - details here.

More information from Jenny McNair jm65@le.ac.uk

Contact Details

Leicester Cancer Research Centre
Robert Kilpatrick Clinical Sciences Building
University of Leicester
Leicester Royal Infirmary
Leicester LE2 7LX

T: +44 (0) 116 252 3170
E: cancerstudies@le.ac.uk

(Please note this email address should not be used for clinical referrals or patient correspondence)

Maps and Directions

Sat Nav users: 
LE1 5WW

Accessibility

AccessAble logo

The University of Leicester is committed to equal access to our facilities. DisabledGo has a detailed accessibility guide for the Robert Kilpatrick Clinical Sciences Building.

Seminars

.